Business Context and Reporting Period
Company: Apyx Medical Corp (APYX)
Filing Type: Form 8-K (Current Report)
Report Date: November 17, 2025
Event Date: November 18, 2025 (Underwriting Agreement); November 19, 2025 (Offering Close)
Context: The Company entered into a material definitive agreement to conduct an underwritten public offering of common stock.
Key Financial Metrics
This filing reports on a capital raise event rather than periodic operating results. Specific metrics include:
- Shares Issued: 2,762,431 shares of Common Stock.
- Offering Price: $3.62 per share.
- Over-Allotment Option: Underwriter granted an option to purchase up to 414,365 additional shares.
- Gross Proceeds: Approximately $9.4 million.
- Underwriting Discount: 6.0% of the public offering price.
- Net Proceeds: Not explicitly stated; calculated as gross proceeds minus the 6.0% discount and other offering expenses.
Note: The filing does not provide current revenue, profit, cash flow, margins, or total debt figures.
Material Changes
The primary material change is the increase in equity capital and share count resulting from the Offering. The Company expects to utilize the net proceeds for:
- Working capital and general corporate purposes.
- Expanding sales and marketing efforts.
- Capital expenditures.
- Acquisitions of complementary businesses, products, or technologies.
- Repaying indebtedness incurred from time to time.
Guidance, Outlook, and Risks
Management Commentary: Management intends to deploy capital toward growth initiatives (sales, marketing, acquisitions) and balance sheet management (debt repayment).
Risks and Contingencies: The Underwriting Agreement contains customary representations, warranties, conditions to closing, and indemnification obligations. The issuance was made pursuant to a Registration Statement on Form S-3 (File No. 333-268532) declared effective in December 2022.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 6.0% underwriting discount and specific offering expenses.
- Confirm whether the underwriter exercised the 414,365 share over-allotment option.
- Review the Company's most recent 10-Q or 10-K for current cash balances and total indebtedness to assess the impact of the new capital.
- Check for any specific details on the "repayment of indebtedness" to determine if specific loans are being retired.